Is quality of life among minimally symptomatic patients with schizophrenia better following withdrawal or continuation of antipsychotic treatment?

Journal of Clinical Psychopharmacology

Volumn 26, Issue 1, 2006, Pages 40-44

  Beasley Jr , Charles M ^a   Sutton, Virginia K ^a   Taylor, Cindy C ^a   Sethuraman, Gopalan ^a   Dossenbach, Martin ^b   Naber, Dieter ^c  

^a ELI LILLY AND COMPANY   (United States)

^b Area Medical Center Vienna   (Austria)

^c UNIVERSITY OF HAMBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE DERIVATIVE; CHOLINERGIC RECEPTOR BLOCKING AGENT; DIAZEPAM; NEUROLEPTIC AGENT; OLANZAPINE; PLACEBO;

AGED; ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC PROCEDURE; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; MENTAL DISEASE; MULTICENTER STUDY; PRIORITY JOURNAL; PROPHYLAXIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RELAPSE; SCHIZOPHRENIA; SCORING SYSTEM;

ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; QUALITY OF LIFE; RECURRENCE; SCHIZOPHRENIA;

EID: 31544482658     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.jcp.0000195109.01898.5e     Document Type: Article

References (8)

1. Bosveld-van Haandel LJ, Slooff CJ, van den Bosch RJ. Reasoning about the optimal duration of prophylactic antipsychotic medication in schizophrenia: evidence and arguments. Acta Psychiatr Scand. 2001;103:335-346.
2. Gilbert P, Harris J, McAdams LA, et al. Neuroleptic withdrawal in schizophrenic patients. Arch Gen Psychiatry. 1995;52:173-188.
3. Harding CM, Zahniser JH. Empirical correction of seven myths about schizophrenia with implications for treatment. Acta Psychiatr Scand Suppl. 1994;384:140-146.
4. Whitaker R. The case against antipsychotic drugs: a 50-year record of doing more harm than good. Med Hypotheses. 2004;62:5-13.
5. Harding CM, Brooks GW, Ashikaga T, et al. The Vermont longitudinal study of persons with severe mental illness, I: methodology, study sample, and overall status 32 years later. Am J Psychiatry. 1987;144:718-726.
6. Beasley CM, Sutton VK, Hamilton SH, et al. A double-blind, randomized, placebo-controlled trial of olanzapine in the prevention of psychotic relapse. J Clin Psychopharmacol. 2003;23:582-594.
7. Heinrichs DW, Hanlon TE, Carpenter WT Jr. The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome. Schizophr Bull. 1984;10:388-398.
8. Retherford RD, Kim Choe M. Path analysis. Statistical Models for Causal Analysis. New York, NY: John Wiley & Sons; 1993:93-99.